Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients?

Clinical Biochemistry

Volumn 45, Issue 1-2, 2012, Pages 3-6

  Eskander, Emad F ^a   Abd Rabou, Ahmed A ^a   Yahya, Shaymaa M M ^a   Shaker, Olfat G ^b   Mohamed, Mervat S ^c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Growth hormone; HCV genotype 4; IFN RBV combination therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA2B INTERFERON PLUS RIBAVIRIN; ASPARTATE AMINOTRANSFERASE; HUMAN GROWTH HORMONE; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CONTROLLED STUDY; FEMALE; GENOTYPE; GROWTH HORMONE DEFICIENCY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMAN GROWTH HORMONE; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROTHROMBIN TIME; RIBAVIRIN;

EID: 84855315255     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.08.1145     Document Type: Article

References (31)

1. WHO Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. J Viral Hepat 1999, 6(1):35-47.
2. WHO Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004, 44(1):20-29.
3. Deuffic-Burban S., Mohamed M., Larouze B., Carrat F., Valleron A. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006, 44(3):455-461.
4. Elkady A., Tanaka Y., Kurbanov F., Sugauchi F., Sugiyama M., Khan A., et al. Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. J Med Virol 2009, 81:1015-1023.
5. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al. Consensus proposals for unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42(4):962-973.
6. Watanabe T., Umehara T., Kohara M. Therapeutic application of RNA interference for hepatitis C virus. Adv Drug Delivery Rev 2007, 59:1263-1276.
7. Plockinger U., Kruger D., Bergk A., Weich V., Wiedenmann B., Berg T. Hepatitis C patients have reduced Growth hormone secretion which improves during long term therapy with pegylated interferon alpha. Am J Gastroenterol 2007, 102(12):2724-2731.
8. Müller H., Hiemke C., Hammes E., Hess G. Sub-acute effects of interferon-α2 on adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in humans. Psychoneuroendocrinology 1992, 17(5):459-465.
9. Gentilucci U.V., Zardi E.M., Caccavo D., Petitti T., Manfrini S., Pozzilli P., et al. TNF-α and growth hormone resistance in patients with chronic liver disease. J Interferon Cytokine Res 2004, 23(5):229-235.
10. Li C.H., Evans H.M. Isolation of pituitary growth hormone. Science 1944, 99:183-184.
11. Le Roith D., Bondy C., Yakar S., Liu J.L., Butler A. The somatomedin hypothesis. Endocr Rev 2001, 22:53-74.
12. Liu N., Mertani H.C., Norstedt G., Tornell J., Lobie P.E. Mode of the autocrine/paracrine mechanism of growth hormone action. Exp Cell Res 1997, 237:196-206.
13. Harvey S., Hull K.L. Growth hormone. A paracrine growth factor?. Endocrine 1997, 7:267-279.
14. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996, 24(2):289-293.
15. Binder G., Wittekindt N., Ranke M.B. Noonan syndrome: genetics and responsiveness to growth hormone therapy. Horm Res 2007, 67(1):45-49.
16. Powers M. Performance-enhancing drugs. Principles of Pharmacology for Athletic Trainers 2005, 331-332.
17. Pennisi P.A., Kopchick J.J., Thorgeirsson S., LeRoith D., Yakar S. Role of growth hormone (GH) in liver regeneration. J Endocrinol 2004, 145(10):4748-4755.
18. Derbala M., Amer A., Bener A., Lopez A., Omar M., El-Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005, 12:380-385.
19. El Makhzangy H., Esmat G., Said M., El Raziky M., Shouman S., Refai S., et al. Response to pegylated interferon alfa-2a ribavirin in chronic hepatitis C genotype 4. Med Virol 2009, 1576-1583.
20. Kamal S., El Tawil A., Nakano T., He Q., Rasenack J., Hakam S., et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005, 54:858-866.
21. Akuta N., Suzuki F., Sezaki H., Hosaka T., Someya T., Kobayashi M., et al. Predective factors of virologic response to interferon-ribavirin combination therpy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006, 78(1):83-90.
22. Seeff L.B. Natural history of hepatitis C. Hepatology 2002, 36(1):S35-S46.
23. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999, 31:9-16.
24. Roudot-Thoraval F., Bastie A., Pawlotsky J.-M., Dhumeaux D., et al. Epidemiological factors affecting the severity of hepatitis C virus-related disease: a French survey of 6,664 patients. Hepatology 1997, 26:485-490.
25. Niederau C., Lange S., Heintges T., Erhars A., Buschkamp M., Hueter D., et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998, 28:1687-1695.
26. Taketa K. Alfafetoprotein: reevaluation in hepatology. Hepatology 1990, 12:1420-1432.
27. Males S., Raafat Gad R., Esmat G., Abobakr H., Anwar M., et al. Serum alpha foetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther 2007, 12:797-803.
28. Davis G.L., Lau J.Y. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997, 26:1225-1275.
29. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989, 321:1501-1506.
30. Glue P., Fang J.W., Rouzier-Panis R., et al. Hepatitis C intervention therapy group. Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000, 68:556-567.
31. Bailon P., Palleroni A., Schaffer C.A., et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001, 12:195-202.